Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | FABP2 | P12104 | 2/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16303954 | 0.88 | PPARA (0.61) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL805971 | 0.88 | PPARA (0.61) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL1305271 | 0.88 | CA1 (0.58) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL1304908 | 0.88 | MEN1 (0.62) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL1305530 | 0.88 | PPARA (0.55) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL9303663 | 0.86 | MEN1 (0.57) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL1304565 | 0.85 | EPHX1 (0.59) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL9130742 | 0.85 | PPARA (0.59) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL1305000 | 0.84 | MAPT (0.68) | PPARAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL1304683 | 0.84 | PPARA (0.61) | PPARAMAPTMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| WO-2008136888-A2 | SECOND GENERATION LOW OXYGEN AFFINITY PEGYLATED HEMOGLOBINS AS OXYGEN-CARRYING PLASMA EXPANDERS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2008-11-13 | — | — | WO | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-8697645-B2 | Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120232120-A1 | AMINO ACID AMIDES OF PHENOXYBUTYRIC ACID DERIVATIVES | LALEZARI IRAJ (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232120-A1 | AMINO ACID AMIDES OF PHENOXYBUTYRIC ACID DERIVATIVES | LALEZARI IRAJ (US) | 2012-09-13 | — | — | US | disclosed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20100216695-A1 | SECOND GENERATION LOW OXYGEN AFFINITY PEGYLATED HEMOGLOBINS AS OXYGEN-CARRYING PLASMA EXPANDERS | NATIONAL INSTITUTES OF HEALTH | 2010-08-26 | — | — | US | disclosed |
| US-5472981-A | Treating hemoglobin or blood in vivo or in vitro to modify the affinity of hemoglobin for oxygen | MONTEFIORE MEDICAL CENTER (US) | 1995-12-05 | — | — | US | disclosed |
| US-5292935-A | Carboxyalkoxy-substituted diphenylurea | MONTEFIORE MEDICAL CENTER (US) | 1994-03-08 | — | — | US | disclosed |
| US-5093367-A | Arylureidophenoxymethylpropionic acids which have activity in dissociation of oxygen from hemoglobin | MONTEFIORE MEDICAL CENTER (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0420930-A4 | METHOD OF SYNTHESIS AND NOVEL COMPOUNDS FOR PHARMACEUTICAL USES | — | 1991-12-04 | — | — | EP | disclosed |
| EP-0420930-A1 | METHOD OF SYNTHESIS AND NOVEL COMPOUNDS FOR PHARMACEUTICAL USES | LALEZARI, Iraj (US) | 1991-04-10 | — | — | EP | disclosed |
| US-4921997-A | Method of synthesis and novel compounds for pharmaceutical uses | MONTEFIORE MEDICAL CENTER (US) | 1990-05-01 | — | — | US | disclosed |
| WO-1989012622-A1 | METHOD OF SYNTHESIS AND NOVEL COMPOUNDS FOR PHARMACEUTICAL USES | LALEZARI IRAJ (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216695-A1 | SECOND GENERATION LOW OXYGEN AFFINITY PEGYLATED HEMOGLOBINS AS OXYGEN-CARRYING PLASMA EXPANDERS | HBG2, HBG1, HBB | PPARA 1286/4885MAPT 2904/4885MEN1 4045/4885 |
| US-20120232120-A1 | AMINO ACID AMIDES OF PHENOXYBUTYRIC ACID DERIVATIVES | SLC1A5, BCAT2, PAH | PPARA 525/4885MAPT 1190/4885MEN1 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.